步长制药：全资子公司6033.80万元委托开展药品注册临床试验

Core Viewpoint - The announcement indicates that the company’s wholly-owned subsidiary, Shandong Danhong Pharmaceutical, has signed a clinical trial outsourcing contract with Beijing Zhuoyue Future for the registration of a new drug, which is expected to enhance the company's research and development capabilities and reduce costs [1] Group 1 - The contract involves a total of 480 cases (including a 20% dropout rate) with a total price of 60.338 million yuan (including tax) [1] - If the final sample size exceeds 520 cases, the additional cases will be charged at a rate of 108,890 yuan per case (including tax) [1] - Shandong Danhong's revenue for 2024 is projected to be 1.331 billion yuan, with a net profit of 226 million yuan; for the first nine months of 2025, revenue is reported at 1.402 billion yuan and net profit at 334 million yuan [1]